Vesting, A.J.* ; Jais, A. ; Klemm, P.* ; Steuernagel, L.* ; Wienand, P.* ; Fog-Tonnesen, M.* ; Hvid, H.* ; Schumacher, A.L.* ; Kukat, C.* ; Nolte, H.* ; Georgomanolis, T.* ; Altmüller, J.* ; Pasparakis, M.* ; Schmidt, A.* ; Krüger, M.* ; Supprian, M.S.* ; Waisman, A.* ; Straub, B.K.* ; Raschzok, N.* ; Bernier, M.* ; Birkenfeld, A.L. ; Hövelmeyer, N.* ; Brüning, J.C.* ; Wunderlich, F.T.*
NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition.
Mol. Metab. 66:101626 (2022)
OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) ranges from steatosis to nonalcoholic steatohepatitis (NASH), which often progresses to hepatocellular carcinoma (HCC) through a largely undefined mechanism. NASH and HCC depend on inflammatory signaling, whose master regulator is the NFκB transcription factor family, activated by canonical and non-canonical pathways. METHODS: Here, we investigated non-canonical NFκB-inducing kinase (NIK/MAP3K14) in metabolic NASH, NASH to HCC transition, and DEN-induced HCC. To this end, we performed dietary and chemical interventions in mice that were analyzed via single nucleus sequencing, gene expression and histochemical methods. Ultimately, we verified our mouse results in human patient samples. RESULTS: We revealed that hepatocyte-specific NIK deficiency (NIKLKO) ameliorated metabolic NASH complications and reduced hepatocarcinogenesis, independent of its role in the NFκB pathway. Instead, hepatic NIK attenuated hepatoprotective JAK2/STAT5 signaling that is a prerequisite for NASH and NASH to HCC progression in mice and humans. CONCLUSIONS: Our data suggest NIK-mediated inhibitory JAK2 phosphorylation at serine 633 that might be amenable for future therapeutic interventions in patients.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Nik In Nash To Hcc Progression ; Nik-mediated Jak2 Inhibition Impairs Stat5 Signaling; Nf-kappa-b; Hepatic Growth-hormone; Fatty Liver-disease; Tyrosine Kinase Jak2; Signal Transducer; Nonalcoholic Steatohepatitis; Protein-kinase; Phosphorylation; Activation; Expression
Keywords plus
Language
english
Publication Year
2022
Prepublished in Year
0
HGF-reported in Year
2022
ISSN (print) / ISBN
2212-8778
e-ISSN
2212-8778
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 66,
Issue: ,
Pages: ,
Article Number: 101626
Supplement: ,
Series
Publisher
Elsevier
Publishing Place
Amsterdam
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30201 - Metabolic Health
90000 - German Center for Diabetes Research
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-555600-001
G-502400-001
Grants
Universität zu Köln
Novo Nordisk
National Institute on Aging
National Institutes of Health
CECAD
Copyright
Erfassungsdatum
2022-12-06